Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/35873
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBRUYNDONCKX, Robin-
dc.contributor.authorStuart, B-
dc.contributor.authorLittle, P-
dc.contributor.authorHENS, Niel-
dc.contributor.authorIeven , M-
dc.contributor.authorButler, C-
dc.contributor.authorVerheij, T-
dc.contributor.authorGoossens, H-
dc.contributor.authorCoenen , S-
dc.date.accessioned2021-11-25T08:27:59Z-
dc.date.available2021-11-25T08:27:59Z-
dc.date.issued2021-
dc.date.submitted2021-09-13T15:19:25Z-
dc.identifier.citationAntibiotics (Basel), 10 (7) (Art N° 817)-
dc.identifier.urihttp://hdl.handle.net/1942/35873-
dc.description.abstractWhile most cases of acute cough are self-limiting, antibiotics are prescribed to over 50%. This proportion is inappropriately high given that benefit from treatment with amoxicillin could only be demonstrated in adults with pneumonia (based on chest radiograph) or combined viral-bacterial infection (based on modern microbiological methodology). As routine use of chest radiographs and microbiological testing is costly, clinical prediction rules could be used to identify these patient subsets. In this secondary analysis of data from a multicentre randomised controlled trial in adults presenting to primary care with acute cough, we used prediction rules for pneumonia or combined infection and assessed the effect of amoxicillin in patients predicted to have pneumonia or combined infection on symptom duration, symptom severity and illness deterioration. In total, 2056 patients that fulfilled all inclusion criteria were randomised, 1035 to amoxicillin, 1021 to placebo. Neither patients with a predicted pneumonia nor patients with a predicted combined infection were significantly more likely to benefit from amoxicillin. While the studied clinical prediction rules may help primary care clinicians to reduce antibiotic prescribing for low-risk patients, they did not identify adult acute cough patients that would benefit from amoxicillin treatment.-
dc.description.sponsorshipGRACE was funded by the European Commission’s Framework Programme 6 (LSHMCT-2005-518226). R.B. is funded as a postdoctoral researcher by FWO Flanders (grant 12I6319N). The work was supported by the Methusalem financing program of the Flemish Government. N.H. acknowledges support from the University of Antwerp scientific chair in Evidence-Based Vaccinology, financed in 2009−2019 by a gift from Pfizer and in 2016–2020 from GSK. We are grateful to key members of the GRACE Project group whose hard work has made this study possible, including Niels Adriaenssens, Jordi Almirall, Zuzana Bielicka, Francesco Blasi, Lidewij Broekhuizen, Pascale Bruno, Slawomir Chlabicz, Jo Coast, Mel Davies, Pim de Jong, An De Sutter, Patricia Fernandez, Maciek Godycki-Cwirko, Iris Hering, Kerenza Hood, Helena Hupkova, Janko Kersnik, Anna Kowalczyk, Christina Lannering, Marieke Lemiengre, Frank Leus, Katherine Loens, Christine Lammens, Bo-Eric Malmvall, Artur Mierzecki, Sigvard Mölstad, Karel Moons, Michael Moore, Magdalena Muras, Nuria Sanchez Romano, Matteu Serra Prat, Tom Schaberg, Richard Smith, Igor Svab, Jackie Swain, Paolo Tarsia, Antoni Torres, Pia Touboul, Saskia van Vugt, Robert Veen, and Tricia Worby, Peter Zuithoff, and all the clinicians and patients who consented to be part of GRACE. Conflicts of Interest: The authors declare no conflict of interest-
dc.language.isoen-
dc.publisherMDPI-
dc.rights2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).-
dc.subject.otheradults-
dc.subject.otheramoxicillin-
dc.subject.otherbenefit of treatment-
dc.subject.otherclinical prediction rule-
dc.subject.otherlower respiratory tract infection-
dc.subject.otherpneumonia-
dc.subject.otherprimary care-
dc.subject.otherviral-bacterial infection-
dc.titleThe Effect of Amoxicillin in Adult Patients Presenting to Primary Care with Acute Cough Predicted to Have Pneumonia or a Combined Viral-Bacterial Infection-
dc.typeJournal Contribution-
dc.identifier.issue7-
dc.identifier.volume10-
local.bibliographicCitation.jcatA1-
local.publisher.placeST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr817-
dc.identifier.doi10.3390/antibiotics10070817-
dc.identifier.isi000676004900001-
local.provider.typeWeb of Science-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorBRUYNDONCKX, Robin-
item.contributorStuart, B-
item.contributorLittle, P-
item.contributorHENS, Niel-
item.contributorIeven , M-
item.contributorButler, C-
item.contributorVerheij, T-
item.contributorGoossens, H-
item.contributorCoenen , S-
item.accessRightsOpen Access-
item.validationecoom 2022-
item.fullcitationBRUYNDONCKX, Robin; Stuart, B; Little, P; HENS, Niel; Ieven , M; Butler, C; Verheij, T; Goossens, H & Coenen , S (2021) The Effect of Amoxicillin in Adult Patients Presenting to Primary Care with Acute Cough Predicted to Have Pneumonia or a Combined Viral-Bacterial Infection. In: Antibiotics (Basel), 10 (7) (Art N° 817).-
crisitem.journal.issn2079-6382-
crisitem.journal.eissn2079-6382-
Appears in Collections:Research publications
Show simple item record

Page view(s)

40
checked on Sep 7, 2022

Download(s)

10
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.